Clinical Pharmacokinetics of 1-[((S)-2-Hydroxy-2-Oxo-1,4,2-Dioxaphosphorinan-5-yl)methyl]cytosine in Human Immunodeficiency Virus-Infected Patients

The pharmacokinetics and bioavailability of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine (cyclic HPMPC) were examined at four doses in 22 patients with human immunodeficiency virus infection. Two groups of six patients received a single dose of cyclic HPMPC at 1.5 or 3.0 mg/k...

Descrizione completa

Dettagli Bibliografici

Pubblicato in:	Antimicrob Agents Chemother
Autori principali:	Cundy, Kenneth C., Barditch-Crovo, Patricia, Petty, Brent G., Ruby, April, Redpath, Murphy, Jaffe, Howard S., Lietman, Paul S.
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	American Society for Microbiology (ASM) 1999
Soggetti:	Antiviral Agents
Accesso online:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC89062/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9925517/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.43.2.271
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!